share_log

Canopy Growth | 8-K: Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

Canopy Growth | 8-K: Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

Canopy Growth | 8-K：Canopy Growth公布2025财年第二季度财务业绩
美股SEC公告 ·  2024/11/08 20:15

Moomoo AI 已提取核心信息

Canopy Growth reported Q2 FY2025 net revenue of $63 million, down 9% year-over-year, while gross margin improved 100 basis points to 35%. The decline was partially offset by 16% growth in Canadian medical cannabis and 12% growth in international markets. Storz & Bickel vaporizer business saw strong 32% revenue growth to $16 million.The company reduced its adjusted EBITDA loss by 54% to $5.5 million, driven by cost savings initiatives. Free cash flow improved 16% to negative $56.4 million. The balance sheet strengthened with cash and short-term investments increasing to $231 million from $195 million in the previous quarter.Looking ahead, management expects accelerated momentum in the second half, supported by the re-introduction of Wana edibles and new product launches. The company remains on track to achieve positive adjusted EBITDA in coming quarters through topline growth and continued cost discipline.
Canopy Growth reported Q2 FY2025 net revenue of $63 million, down 9% year-over-year, while gross margin improved 100 basis points to 35%. The decline was partially offset by 16% growth in Canadian medical cannabis and 12% growth in international markets. Storz & Bickel vaporizer business saw strong 32% revenue growth to $16 million.The company reduced its adjusted EBITDA loss by 54% to $5.5 million, driven by cost savings initiatives. Free cash flow improved 16% to negative $56.4 million. The balance sheet strengthened with cash and short-term investments increasing to $231 million from $195 million in the previous quarter.Looking ahead, management expects accelerated momentum in the second half, supported by the re-introduction of Wana edibles and new product launches. The company remains on track to achieve positive adjusted EBITDA in coming quarters through topline growth and continued cost discipline.
Canopy Growth报告了2025财年第二季度净营业收入为6300万，较上年同期下降9%，而毛利率提高了100个基点至35%。萎缩部分被加拿大医疗大麻16%的增长和国际市场12%的增长部分抵消。Storz & Bickel的蒸汽吸入器业务实现了32%的强劲收入增长，达1600万。公司将其经调整的EBITDA损失减少了54%，降至550万，这得益于成本节约措施。自由现金流改善了16%，为负5640万。资产负债表得到了加强，现金和短期投资从上个季度的19500万增加至23100万。展望未来，管理层预计下半年会加速增长，特别是Wana食品的重新推出和新产品的上市将为其提供支持。公司仍在轨道上，预计将在未来几个季度实现积极的经调整EBITDA，得益于营业收入增长和持续的成本控制。
Canopy Growth报告了2025财年第二季度净营业收入为6300万，较上年同期下降9%，而毛利率提高了100个基点至35%。萎缩部分被加拿大医疗大麻16%的增长和国际市场12%的增长部分抵消。Storz & Bickel的蒸汽吸入器业务实现了32%的强劲收入增长，达1600万。公司将其经调整的EBITDA损失减少了54%，降至550万，这得益于成本节约措施。自由现金流改善了16%，为负5640万。资产负债表得到了加强，现金和短期投资从上个季度的19500万增加至23100万。展望未来，管理层预计下半年会加速增长，特别是Wana食品的重新推出和新产品的上市将为其提供支持。公司仍在轨道上，预计将在未来几个季度实现积极的经调整EBITDA，得益于营业收入增长和持续的成本控制。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Citius Oncology
    CTOR
    -- 0.930
    脑再生科技
    RGC
    -- 31.880
    正业生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood医药
    IRWD
    -- 1.470
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日